Marc Cohen Net Worth

The estimated Net Worth of Marc A Cohen is at least $6.67 million dollars as of 18 February 2021. Mr. Cohen owns over 536 units of Frequency Therapeutics Inc stock worth over $1,670 and over the last 21 years he sold FREQ stock worth over $6,350,716. In addition, he makes $313,965 as Lead Independent Chairman of the Board Director at Frequency Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cohen FREQ stock SEC Form 4 insiders trading

Marc has made over 92 trades of the Frequency Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 536 units of FREQ stock worth $1,131 on 18 February 2021.

The largest trade he's ever made was exercising 100,000 units of Frequency Therapeutics Inc stock on 14 July 2011 worth over $1,059,000. On average, Marc trades about 6,843 units every 50 days since 2003. As of 18 February 2021 he still owns at least 5,566 units of Frequency Therapeutics Inc stock.

You can see the complete history of Mr. Cohen stock trades at the bottom of the page.

Marc Cohen biography

Marc A. Cohen serves as Lead Independent Chairman of the Board Director of the Company. Since 2012, Mr. Cohen has served as the Chief Executive Officer of Bublup, Inc., an online knowledge-sharing platform, as well as CoBro Ventures, Inc., an investment management company. Mr. Cohen is also Executive Chairman of C4 Therapeutics and Mana Therapeutics. Mr. Cohen holds an M.S. in Electrical Engineering from Stanford University and a Bachelor’s degree in Engineering Science from Harvard University.

What is the salary of Marc Cohen?

As the Lead Independent Chairman of the Board Director of Frequency Therapeutics Inc, the total compensation of Marc Cohen at Frequency Therapeutics Inc is $313,965. There are 7 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.

How old is Marc Cohen?

Marc Cohen is 56, he's been the Lead Independent Chairman of the Board Director of Frequency Therapeutics Inc since 2019. There are 6 older and 11 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.

What's Marc Cohen's mailing address?

Marc's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN, MA, 02472.

Insiders trading at Frequency Therapeutics Inc

Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer et Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.

What does Frequency Therapeutics Inc do?

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.

Complete history of Mr. Cohen stock trades at Opiant Pharmaceuticals Inc, Frequency Therapeutics Inc et C4 Therapeutics

Frequency Therapeutics Inc executives and stock owners

Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:

• David Lucchino,
  President, Chief Executive Officer, Co-Founder, Director
• Christopher Loose,
  Co-Founder, Chief Scientific Officer
• Carl LeBel,
  Chief Development Officer
• David L. Lucchino,
  Co-Founder, Pres, CEO & Director
• Wendy S. Arnold,
  Chief People Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Robert Langer,
  Independent Director
• Marc Cohen,
  Lead Independent Chairman of the Board Director
• Joel Marcus,
  Independent Director
• Michael Huang,
  Independent Director
• Timothy Barberich,
  Independent Director
• Carlo Tanzi,
  IR Contact Officer
• Cynthia Feldmann,
  Independent Director
• Dana Hilt,
  Chief Medical Officer
• Ajay Rai,
  Vice President - Business Development
• Richard Mitrano,
  Vice President of Finance and Operations
• Wendy Arnold,
  Chief People Officer
• William Mclean,
  Co-Founder, Vice President - Biology and Regenerative Medicine
• Dr. Carl P. LeBel,
  Chief Devel. Officer
• Dr. Christopher R. Loose,
  Co­-Founder & Chief Scientific Officer
• Dr. William W. Chin M.D.,
  Sr. VP of Translational Medicine
• Dr. Dana C. Hilt,
  Chief Medical Officer
• Dr. Jeff Hrkach,
  Sr. VP of Technology Devel.
• Richard J. Mitrano,
  VP of Fin. & Operations
• William J. McLean Ph.D.,
  Co-founder & Sr. VP of Hearing Biology and Translational Research
• Quentin Mc Cubbin,
  Chief Manufacturing Officer
• James E Deerfield Mgmt L.P....,
  
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Michael Bookman,
  General Counsel and Secretary